跳至主要内容
临床试验/NCT06553729
NCT06553729招募中不适用

Effects of Vitamin D and Prebiotic Supplementation on Glucose Control During Pregnancy: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Huazhong University of Science and Technology2 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2025年2月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
招募中
入组人数
500
试验地点
2
主要终点
Concentration of fasting blood glucose

研究概览

简要总结

The goal of this randomized, double-blind, placebo-controlled study included pregnant women at high risk of GDM at 6-15 weeks of gestation is to investigate whether supplementation with vitamin D (1600 IU per day) or prebiotics (inulin, 10 gram per day) during pregnancy has beneficial effects on controlling blood glucose during pregnancy.

详细描述

The goal of this randomized, double-blind, placebo-controlled study included pregnant women at high risk of GDM at 6-15 weeks of gestation is to investigate whether supplementation with vitamin D (1600 IU per day) or prebiotics (inulin, 10 gram per day) during pregnancy has beneficial effects on controlling blood glucose during pregnancy.

About 500 pregnant women aged 18-45 years, at 6-15 weeks of gestation, had resided locally for at least one year, with high risk of GDM will be enrolled in the study. Pregnant women at high risk of GDM are defined as meeting any of the following criteria:

  1. Pre-pregnancy body mass index (BMI) ≥24.0 kg/m2;
  2. History of GDM or a family history of diabetes;
  3. History of delivery of macrosomia (birth weight >4000 g);
  4. Glycated hemoglobin (HbA1c) 5.7-6.4% or fasting blood glucose 5.6-7.0 mmol/L; Eligible participants must have singleton pregnancy, no infertility treatment, no history of diabetes or a definite diagnosis of diabetes, or impaired glucose tolerance at recruitment (fasting blood glucose >7.0 mmol/L or HbA1c≥6.5%), no allergic history of chicory root and they will be required to agree to limit the use of vitamin D, prebiotics, probiotics, or synbiotic supplementations and to be convenient access to study centers. Safety exclusions include serious chronic or infectious diseases, serious liver or kidney disease, abnormalities in calcium metabolism, and clinically diagnosed mental disorders, or other conditions that would preclude participation.

Eligible participants will be assigned by chance to one of four groups: (1) daily vitamin D (1600 IU) and prebiotics (10 gram); (2) daily vitamin D (1600 IU) and prebiotics placebo; (3) daily vitamin D placebo and prebiotics (10 gram); or (4) daily vitamin D placebo and prebiotics placebo. Randomization will be conducted.

At enrollment, baseline questionnaires are designed to collect data on sociodemographic factors, pregnancy-related information, lifestyle habits, health status, and medical conditions before and during pregnancy. Participants in all groups will take two capsules that contained either vitamin D or vitamin D placebo and a strip of prebiotics powder (10 g per strip, brew with warm water and take with meals) or prebiotics placebo each day until delivery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • 6-15 weeks of gestation.
  • Age 18-45 years old.
  • Permanent resident or resident locally at least one year.
  • GDM high-risk pregnant women (meeting any of the following criteria):
  • Pre-pregnancy body mass index (BMI) ≥24.0 kg/m2,
  • History of GDM or a family history of diabetes,
  • History of delivery of macrosomia (birth weight >4000 g),
  • HbA1c 5.7-6.4% or fasting blood glucose 5.6-7.0 mmol/L.

排除标准

  • Multiple pregnancy.
  • Have received infertility treatment such as in vitro fertilization or intrauterine insemination.
  • History of diabetes or current diagnosis of diabetes (including type 1 and type 2 diabetes) or abnormal glucose tolerance at recruitment (fasting blood glucose >7.0 mmol/L or HbA1c≥6.5%).
  • Serious chronic diseases (including cardiovascular and cerebrovascular diseases, cancer, and thyroid dysfunction) or infectious diseases (including hepatitis B, active tuberculosis, acquired immunodeficiency syndrome, and syphilis).
  • Severe liver disease (such as cirrhosis) or severe kidney disease (such as renal failure or requiring dialysis).
  • Kidney stones, hypercalcemia, hypercalciuria, parathyroid hormone abnormality.
  • Any mental disorders, such as schizophrenia, depression, other mental disorders, or bipolar disorder.
  • History of allergy or intolerance to vitamin D, chicory root, or starch.
  • Have participated in or are participating in other clinical trials within the past 3 months.
  • Daily vitamin D intake >800 IU.
  • Inability or refusal to answer and communicate.
  • Those who are unwilling to sign the informed consent.
  • The researcher thinks that it is not suitable to participate in this research.

研究组 & 干预措施

Prebiotics +Vitamin D3 placebo

Active Comparator

Prebiotics (inulin), 10g per day. Vitamin D3 placebo.

干预措施: Prebiotics (Dietary Supplement)

Vitamin D3 + Prebiotics

Active Comparator

Vitamin D3 (cholecalciferol), 1600 IU per day. Prebiotics (inulin), 10g per day.

干预措施: Vitamin D3 (Drug)

Vitamin D3 + Prebiotics

Active Comparator

Vitamin D3 (cholecalciferol), 1600 IU per day. Prebiotics (inulin), 10g per day.

干预措施: Prebiotics (Dietary Supplement)

Vitamin D3 + Prebiotics placebo

Active Comparator

Vitamin D3 (cholecalciferol), 1600 IU per day. Prebiotics placebo.

干预措施: Vitamin D3 (Drug)

Vitamin D3 + Prebiotics placebo

Active Comparator

Vitamin D3 (cholecalciferol), 1600 IU per day. Prebiotics placebo.

干预措施: Prebiotics placebo (Dietary Supplement)

Prebiotics +Vitamin D3 placebo

Active Comparator

Prebiotics (inulin), 10g per day. Vitamin D3 placebo.

干预措施: Vitamin D3 placebo (Dietary Supplement)

Vitamin D3 placebo + Prebiotics placebo

Placebo Comparator

Vitamin D3 placebo. Prebiotics placebo.

干预措施: Prebiotics placebo (Dietary Supplement)

Vitamin D3 placebo + Prebiotics placebo

Placebo Comparator

Vitamin D3 placebo. Prebiotics placebo.

干预措施: Vitamin D3 placebo (Dietary Supplement)

结局指标

主要结局

Concentration of fasting blood glucose

时间窗: 24-28 gestational weeks, 32-36 gestational weeks, and delivery

Concentration of fasting blood glucose, measured in mmol/L

Glycated hemoglobin (HbA1c)

时间窗: 24-28 gestational weeks, 32-36 gestational weeks, and delivery

Concentration of HbA1c, measured in the percentage of hemoglobin

次要结局

  • Concentration of C-reactive protein (CRP)(24-28 gestational weeks, 32-36 gestational weeks, and delivery)
  • Gestational duration(Delivery)
  • Concentration of blood lipids(24-28 gestational weeks, 32-36 gestational weeks, and delivery)
  • Metagenomic analysis of the gut microbiota(24-28 gestational weeks, 32-36 gestational weeks, and delivery)
  • Birth weight(Delivery)
  • Incidence of Gestational Diabetes(24-28 gestational weeks)
  • Concentration of interleukin-6 (IL-6)(24-28 gestational weeks, 32-36 gestational weeks, and delivery)
  • Concentration of plasma 25(OH)D(24-28 gestational weeks, 32-36 gestational weeks, and delivery)
  • Delivery mode(Delivery)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

An Pan

Professor

Huazhong University of Science and Technology

研究点 (2)

Loading locations...

相似试验